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Background: The identification of circulating tumour cells (CTCs) in peripheral blood is a useful approach to
estimate prognosis, monitor disease progression, and measure treatment effects in various malignancies. However,
clinical relevance of CTCs is controversial. We attempted to detect viable CTCs in the peripheral blood of gastric
cancer patients using a telomerase-specific viral agent.
Methods: We took a 7.5-ml blood sample from 65 treatment-negative gastric cancer patients before surgery and
10 healthy volunteers. We detected viable CTCs in the blood samples after incubating them with a telomerase-
specific, replication-selective, oncolytic adenoviral agent carrying the green fluorescent protein (GFP) gene (OBP-
401). GFP-positive CTCs were defined as having a diameter of at least 7.735 μm; this threshold was determined by
receiver operating characteristic curve analysis. GFP-positive cells were counted under a fluorescence microscope.
Results: There was a significant difference in overall survival among the patients with 0–4 and those with ≥5
GFP-positive CTCs in the stage I–IV disease group and stage II–IV advanced disease group. The number of
GFP-positive CTCs was not related to cancer stage. Among the pathological findings, the number of GFP-positive
CTCs was only significantly related to venous invasion, although there were trends towards more GFP-positive CTCs
with disease progression (tumour depth, lymph node metastasis, distant metastasis, lymphatic invasion, and
histological type).
Conclusions: There was a significant relationship between the number of GFP-positive CTCs and overall survival in
the patients with gastric cancer. The detection of CTCs using OBP-401 may be useful for prognostic evaluation.
Trial registration: University Hospital Medical Information Network in Japan, UMIN000002018.
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Distant metastasis of a solid tumour is a strong prognos-
tic factor [1-3]. The existence of circulating tumour cells
(CTCs) in peripheral blood suggests that a patient is in a
systemic disease phase [4]. The identification of CTCs in
peripheral blood is a useful approach to estimate progno-
sis, monitor disease progression, and measure treatment* Correspondence: h.ito@med.showa-u.ac.jp
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reproduction in any medium, provided the oreffects in breast, prostate, skin, colon and gastrointestinal
malignancies. Therefore, various methods have been
developed to detect CTCs, and are occasionally used in
combination. Common techniques for the enrichment
and detection of CTCs are density gradient separation
[5], direct enrichment by filtration [6,7], immunomag-
netic separation [8], flow cytometry [9], real-time reverse
transcriptase polymerase chain reaction (RT-PCR)
[10,11], and microchip technology [12].
Cell enrichment by density gradient separation is per-
formed using commercial kits such as OncoQuickWThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Protocol and procedure of the “GFP-CTC Assay”. Each
7.5-ml peripheral vein blood sample was obtained from patients
before surgery and from volunteers. The samples were drawn into
tubes containing citric acid, phosphoric acid and dextrose. The
samples were centrifuged and the plasma phase was removed. After
cell washing using PBS and Roswell Park Memorial Institute medium,
the samples were infected with 4 × 108 PFU of OBP-401 virus. OBP-
401 virus was inactivated and cells were fixed with 2%
paraformaldehyde (PFA). The samples were treated with a surface-
active agent to degrade red and white blood cells. Two glass slide
samples from 7.5 ml blood were prepared for microscopic analysis.
All GFP-positive cells on the two slides were counted using a
computer-controlled fluorescent microscope.
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prepW (Nycomed, Oslo, Norway) [14]. Density gradient
separation is based on the theory that different types of
cells can be separated according to their density. There-
fore, it is difficult to extract all CTCs because of cell mi-
gration. RT-PCR is one of the most common methods of
tumour cell detection because of its high sensitivity and
specificity, assuming adequate primer and probe design.
However, false-positive results may occur because of its
technical delicacy and high sensitivity [15,16].
Immunomagnetic cell enrichment, such as that per-
formed by the CellSearch SystemW (Veridex, LLC, Raritan,
NJ, USA) [17], is currently the most commonly used tech-
nique to enrich and detect CTCs [18-21]. The advantage
of immunomagnetic cell separation is that CTCs can be
visualised with a fluorescent microscope. Cells detected
with antibodies against epithelial markers (epithelial cell
adhesion molecules; EpCAMs) are determined to be
CTCs. Therefore, this technique can provide false-positive
results based on normal epithelial marker expression by
non-tumour cells, and false-negative results can arise
based on the lack of selective marker expression on
tumour cells. As a result of the limitations associated with
the above approaches, a new technique is needed to detect
viable CTCs precisely.
Telomerase plays important roles in carcinogenesis, can-
cer invasion, and metastasis [22-24]. We have developed a
technique to exploit high telomerase activity in cells. This
technique uses a telomerase-specific, replication-selective
modified viral agent (OBP-401; TelomeScanW, Oncolys
BioPharma, Tokyo, Japan) in which the human telomerase
reverse transcriptase (TERT) gene promoter is inserted into
the E1 region, and the green fluorescent protein (GFP)
gene is placed under the control of the cytomegalovirus
promoter in the E3 region as a marker of viral replication
[25]. It has been reported that OBP-401 can be used to de-
tect viable CTCs among normal blood cells [26,27].
Here, we applied the assay to detect viable CTCs with
the potential for metastasis in gastric cancer patients.
We detected GFP-positive CTCs. In contrast, it is pos-
sible that non-cancer cells emit GFP fluorescence after
Figure 2 GFP signal intensities from various cancer cell lines. The bottom and top of the box are the lower and upper quartiles, and the
band of the box is the median. The lines on the end of the whiskers are minimum and maximum. The y axis represents GFP signal intensity on a
log scale.
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ger than a threshold determined by comparison between
healthy volunteers and patients, because CTCs are larger
than normal blood cells [7,29,30]. We studied the associ-
ation of GFP-positive CTC number with survival and
pathological indices of disease progression.
Methods
Patients and healthy volunteers
The patients included in this preliminary study were those
undergoing planned surgical treatment; patients who were
suitable for endoscopic mucosal resection or endoscopic
submucosal dissection were excluded. The inclusion
criteria were: (i) histologically proven adenocarcinoma of
the stomach by endoscopic biopsy; (ii) clinical solitary
tumour; (iii) no prior endoscopic resection, chemotherapy,
or radiotherapy; (iv) age 20–80 years; (v) Eastern Co-
operative Oncology Group performance status [31] 0 or 1;
(vi) sufficient organ function; and (vii) written informed
consent. The exclusion criteria were: (i) synchronous or
metachronous malignancy; (ii) pregnant or breastfeeding
women; (iii) active or chronic viral hepatitis; (iv) active
bacterial or fungal infection; (v) diabetes mellitus; (vi) sys-
temic administration of corticosteroids; and (vii) unstable
hypertension. The disease stage in the patients was patho-
logically characterised using the seventh edition of the
TNM classification of the International Union Against
Cancer [32]. The depth of the tumour in three patients
without gastrectomy and the regional lymph node status
of five patients without sufficient lymphadenectomy were
diagnosed surgically.
All the patients attended our hospital regularly after
surgery, and were checked every 3 months. The patients
also underwent endoscopy and computed tomography at
least once a year, according to their disease stage and
course.We also recruited healthy volunteers to act as controls.
All healthy volunteers were employees of Sysmex Cor-
poration and included seven men (mean age 31.4 years,
range 24–39 years) and three women (mean age
33.7 years, range 26–48 years). All volunteers underwent
medical check-ups upon employment and annually;
check-ups included medical interviews, auscultation,
chest radiographs, and blood and urine analyses. Fur-
thermore, we performed individual interviews before
sample collection; any volunteer who was currently re-
ceiving medical treatment, pregnant or breastfeeding, or
who had donated blood within the past month was
excluded.Virus
OBP-401, a telomerase-specific, replication-selective
adenoviral agent in which the TERT promoter element
drives the expression of the EIA and EIB genes, and into
which the GFP gene is integrated, was used in this
study. Sensitivity and specificity of the assay using OBP-
401 have been studied previously by Kim et al. [27]. The
test was repeated five times test in the sample including
1 MDA-MB-468 (breast carcinoma) cells and 7.5 ml
blood, and the numbers of GFP-positive cells were 1, 1,
1, 2 and 3; in the sample including 20 MDA-MB-468
(breast carcinoma) cells, the numbers of GFP-positive
cells were 15, 17, 19, 22 and 24. Viral samples were
stored at −80°C.Cell lines and culture
The A549 (lung carcinoma), HepG2 (hepatocellular
carcinoma), HEC-1 (endometrial adenocarcinoma),
KATO-III (gastric carcinoma), and SBC-3 (small cell lung
carcinoma) cell lines were obtained from the Health
Science Research Resources Bank (Osaka, Japan). The
Table 1 Patient characteristics and pathological findings













































† Well or moderately differentiated adenocarcinoma and papillary
adenocarcinoma were categorized as differentiated type. Signet-ring cell
carcinoma, poorly differentiated adenocarcinoma and mucinous
adenocarcinoma were categorized as undifferentiated type.
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ian carcinoma) cell lines were obtained from the Riken
Cell Bank (Tokyo, Japan). The cells were cultured accord-
ing to the vendor’s specifications. MDA-MB-468 cells
were cultured as previously described [27].Sample preparation and cell counting
A 7.5-ml peripheral vein blood sample was obtained
from each patient before surgery and from each volun-
teer. The samples were drawn into tubes containing citric
acid, phosphoric acid, and dextrose, and stored at 4°C.
The assay was started within 48 h.
The samples were centrifuged for 5 min at 540 g and
the plasma phase was removed. The cells were then
washed four times with phosphate-buffered saline (PBS)
and twice with Roswell Park Memorial Institute medium.
The samples were infected with 4 × 108 plaque-forming
units (PFU) of OBP-401 viruses by incubation in the
medium for 24 hours at 37°C.
After dead cell staining by the red-fluorescent reactive
dye L23102 (Life Technologies Corporation, Carlsbad,
CA, USA), OBP-401 viruses were inactivated and cells
were fixed with 2% paraformaldehyde (PFA) for 20 min
at room temperature.Figure 3 Comparison of cell diameter between patients and
volunteers. To determine the threshold, we compared the
diameters of cells from gastric cancer patients and controls by ROC
analysis. There was a significant difference between the gastric
cancer patients and the controls (p < 0.001; area under the
curve = 0.57; 95% confidence interval = 0.54–0.60).
Figure 4 Examples of microscopic images. Representative images from two gastric cancer samples of GFP-positive CTCs and
immunocytochemical analysis of anti-EpCAM- and anti-CD45-positive cells. Cells were counted using a computer-controlled fluorescence
microscope by an examiner blinded to the sample status. Scale bar, 10 μm.
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(Emalgen 2025 G; Kao Chemicals, Tokyo, Japan) for
10 min at 40°C to degrade red blood cells. Finally, 7.5 ml
blood was used to create two glass slide samples for
microscopic analysis. All GFP-positive cells on the two
slides were counted, using a computer-controlled fluor-
escent microscope (IX71; Olympus, Tokyo, Japan) and
an examiner blinded to the sample details. The total
assay time was 27.5 h (Figure 1).
Determination of GFP fluorescence intensity threshold
The threshold for GFP fluorescence intensity was deter-
mined as follows. Approximately 30,000 cultured cells
were spiked into 7.5-ml blood samples from healthy
volunteers, which were spiked with various cancer cell
lines: A549, HepG2, HEC-1, KATO-III, SBC-3, LNCaP,
MDA-MB-MB468 and OVCAR-3. Blood samples were
subjected to CTC detection assay, and then detectable
cells were counted by fluorescence microscopy. Morethan 100 cells were analysed in each sample. We deter-
mined 2.85 × 107 mean equivalent fluorochrome to be
the threshold for GFP signal intensity from the minimal
GFP intensity level observed in the blood samples spiked
with the cell lines (Figure 2). Data are reported as the
numbers of GFP-positive CTCs per 7.5-ml peripheral
blood sample.Immunostaining
Phycoerythrin-labelled anti-human CD45 antibody
(BioLegend, San Diego, CA, USA) was diluted 1:5 and
Pacific Blue-labelled anti-human CD326 (EpCAM) anti-
body (BioLegend) was diluted 1:10 in PBS containing
2% foetal bovine serum. Cells were incubated with
diluted antibodies for 30 min at 25°C. After washing
with PBS containing 2% foetal bovine serum, cells were
mounted on glass slides and analysed using a fluores-
cence microscope (IX71; Olympus).
Figure 5 Number of GFP-positive cells. The dots are the numbers
of GFP-positive CTCs in the patient samples. The bottom and top of
the box represent the lower and upper quartiles, and the band
across the box shows the median. The lower and upper bars at the
ends of the whiskers show the lowest data point within 1.5
interquartile ranges of the lower quartile, and the highest data point
within 1.5 interquartile ranges of the upper quartile, respectively. The
green bars indicate mean value.
Table 2 Clinicopathological characters of two patient
groups by number of CTCs
Number of CTCs 0 - 4 5 ≤ P value
Number of subjects 41 24
TNM: Stage 0.1586
Stage I 29 11
Stage II 4 2
Stage III 4 6
Stage IV 4 5










TNM: M category 0.2121
M0 37 19
M1 4 5
Main histological type 0.6844
Differentiated type 15 10










Curative resection 38 19
Non-curative resection 1 3




* * Significant difference.
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Statistical analysis was performed using JMP Statistical
Discovery 9.0.2 (SAS Institute, Cary, NC, USA). To deter-
mine the cell diameter threshold, the detected GFP-
positive CTCs were analysed using a receiver operating
characteristic (ROC) curve between the samples from gas-
tric cancer patients and those from volunteers. For mul-
tiple group comparisons, homogeneity of variance was
assessed by the Levene test. For parametric comparisons
we used analysis of variance, and for non-parametric com-
parisons we used the Wilcoxon and the Kruskal–Wallis
tests. We used Fisher’s exact and χ2 tests with a 2 × 2 and
a 4 × 2 table, respectively, to compare the clinicopatholo-
gical characters in the patient group. Kaplan–Meier curves
of estimated disease-free survival and overall survival were
generated, and comparisons among the groups were per-
formed using a two-sided log-rank test. P values ≤0.05
were considered statistically significant.
The study was approved by the Institutional Review
Board of the Showa University, Northern Yokohama
Hospital. We explained the study protocol to the patients
and volunteers before they gave written informed
consent. This study was registered with the University




Sixty-five patients with gastric adenocarcinoma (46 men
and 19 women; mean age 58.8 years, range 33–76 years)who underwent surgery at the Digestive Disease Center
of the Showa University Northern Yokohama Hospital
between September 2009 and May 2011 were included
in this study. Twenty-nine had distal gastrectomy, 32
had total gastrectomy, and four had exploratory laparot-
omy. The patients’ characteristics are summarised in
ab
Figure 6 Overall survival. (a) Overall survival of all patients. (b)
Overall survival of patients with stage II–IV disease. Survival was
compared according to the number of CTCs using Kaplan–Meier
analysis and the log-rank statistics. **p < 0.01, * p < 0.05.
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chemotherapy after surgery. The control group com-
prised 10 healthy volunteers.GFP-positive CTCs in peripheral blood
Using a fluorescence microscope, cells with fluorescent
emissions ≥2.85 × 107 mean equivalent fluorochrome
were counted as GFP-positive cells.
Various sizes of GFP-positive cells were observed in
each sample; therefore, it was difficult to identify one
representative cell among the GFP-positive cells for
comparison between patients and healthy volunteers.
Therefore, to avoid using an arbitrary value, we decided
to use the optimum threshold derived from the ROC
analysis based on the cell size, that is, 7.735 μm, as the
threshold to define GFP-positive CTCs (Figure 3).
By immunohistochemical staining using anti-EpCAM
and anti-CD45 antibodies, we confirmed that GFP-
positive CTCs were EpCAM-positive and CD45-negative
(Figure 4).The numbers of GFP-positive CTCs in the peripheral
blood samples are shown in Figure 5. There was no sig-
nificant difference among the detection rates of GFP-
positive CTCs in the samples representing each cancer
stage.
Association of GFP-positive CTCs with survival
The mean number of GFP-positive CTCs in the samples
from 10 healthy volunteers was 4.8. We divided the
patients into two groups based on the numbers of GFP-
positive CTCs: 0–4 and ≥5. The clinicopathological
characteristics of the two groups are summarised in
Table 2. There was no significant difference between the
two groups except that there was only one category of
lymphatic metastasis.
Figure 6a shows the Kaplan–Meier curves for overall
survival in the two groups: the patients with 0–4 CTCs
and those with ≥5. There was a significant difference be-
tween the two groups (p = 0.0021). Furthermore, in the
advanced gastric cancer patients with stage II–IV dis-
ease, there was a significant difference between the two
groups (p = 0.0126) (Figure 6b).
Association of GFP-positive CTCs with pathological
indices
There was no significant relationship between the number
of GFP-positive CTCs and cancer stage (p = 0.2313)
(Figure 5). Although no statistical significance was
observed, the number of GFP-positive CTCs tended to in-
crease with the progression of the primary tumour (p =
0.1521) (Figure 7a). The number of CTCs in the samples
from the node-positive patients was greater than that in
the node-negative patients (p = 0.1752) (Figure 7b). Com-
pared with the patients without distant metastases, those
with distant metastases had similar numbers of GFP-
positive CTCs (p = 0.5655) (Figure 7c). There was not a
significant difference between the differentiated and undif-
ferentiated type (p = 0.8387) (Figure 7d). The numbers of
CTCs were similar in the samples from patients with and
without lymphatic invasion (p = 0.2054) (Figure 7e). For
venous invasion, the number of CTCs in the samples from
the patients with invasion was significantly higher than
that in patients without invasion (p = 0.0351) (Figure 7f).
Discussion
This paper reports the correlation between CTCs and
gastric cancer, which is the second leading cause of
cancer-related death worldwide. The usefulness of the
detection of CTCs in the diagnosis, estimation of prog-
nosis, and evaluation of treatment effects has already
been reported for breast [27,33], prostate [34], lung [35]
and digestive tract [11,36,37] cancers. This study indi-
cates that it is also useful for gastric cancer.
Figure 7 Relationship between number of GFP-positive CTCs in a 7.5-ml blood sample from gastric cancer patients and pathological
findings in the patients. The dots are the numbers of GFP-positive CTCs in the patient samples. The bottom and top of the box represent the
lower and upper quartiles, and the band across the box shows the median. The lower and upper bars at the ends of the whiskers show the
lowest data point within 1.5 interquartile ranges of the lower quartile, and the highest data point within 1.5 interquartile ranges of the upper
quartile, respectively. a, Tumour invasion depth (T1–T4 indicate increasing depth). b, Lymphatic metastasis (N0 = negative, N1–3 = positive).
c, Distant metastasis (M0 = negative, M1 = positive). d, Histological type (differentiated type and undifferentiated type). e, Lymphatic invasion
(L0 = negative, L1 = positive). f, Venous invasion (V0 = negative, V1 = positive), *p < 0.05. Although only venous invasion displayed a statistically
significant difference, there were some trends towards an increase in CTC number with increasing disease progression.
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lationship between the number of CTCs and prognosis.
Although we used a short follow-up period, the progno-
sis of patients who had ≥5 CTCs in their 7.5-ml periph-
eral blood samples was poor. Patients with early stage
disease generally have a lower recurrence rate [38], and
those with stage I disease actually had no recurrence in
our study. We also calculated survival rate in advanced
gastric cancer patients with stage II–IV disease, and
showed that these patients had a similar survival pattern
to those with stage I–IV disease. These results suggest
that preoperative chemotherapy or comprehensive treat-
ment is appropriate for advanced disease patients who
have many CTCs in pretreatment samples because of
their poor prognosis.Among our pathological findings, only venous invasion
had a significant relationship with the number of CTCs.
This suggests agreement between traditional pathology
and modern molecular technology. We believe that the
lack of a significant difference between the number of
CTCs detected by our assay and the other pathological
indices can be explained by methodological issues such
as the small sample size. Our technique worked well as
a prognostic evaluation tool — to provide information
about the need for postoperative adjuvant therapy —
and it may provide a useful auxiliary tool to pathology-
based classification.
It is not clear whether all detected CTCs have meta-
static potential. Viable CTCs were detected in the sam-
ples from early-stage cancer patients in the present
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without recurrence [38]. We intend to confirm whether
resistant cancer cells, like cancer stem cells, were
present in the detected GFP-positive cells. Also, we will
analyse the functions of viable CTCs individually after
cell sorting, and identify CTCs with metastatic potential
using additional tools such as DNA ploidy analysis
[39,40]. Furthermore, gene expression profiling among
viable CTCs, dead cells, primary tumours, and meta-
static tumours will reveal important information related
to the mechanisms of cancer metastasis.
Our results must be interpreted with some caution,
considering the limitations of this study. First, the num-
ber of CTCs varied widely between individuals, including
patients and healthy volunteers. Moreover, it was not
influenced by tumour stage or the presence of clinically
detectable metastases. Similarly, there was no association
between the presence of metastases (lymph node or dis-
tant) or invasion and the number of CTCs, which brings
into question the use of CTCs to predict metastatic po-
tential. However, it is possible that the relatively small
sample size limited the potential to detect real differ-
ences between these groups of patients. Finally, it must
be acknowledged that our results are only applicable to
preoperative, treatment-naïve gastric cancer and should
not be generalised to other types of cancer.
Clearly, more studies in a larger population of patients,
and with different cancer types, are needed to clarify the
clinical applicability of CTC detection. We are now pre-
paring a study to investigate the effects of gastric cancer
treatment on the number of CTCs, which should help to
establish their relationship with future disease progres-
sion and whether CTC count can help guidetherapy
choice.Conclusions
There was a significant difference in survival between
patients with 0–4 CTCs and those with ≥5. However, it
is unclear whether all CTCs have true metastatic poten-
tial, and further studies are needed.
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